zoledronic acid has been researched along with Neurofibromatosis 1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bobyn, JD; Deo, N; Little, DG; Schindeler, A | 1 |
| Cheng, TL; Deo, N; Little, DG; Mikulec, K; Peacock, L; Schindeler, A | 1 |
| Bobyn, J; Kathy, M; Little, DG; Rasch, A; Schindeler, A | 1 |
| Baldock, PA; Birke, O; Little, DG; Morse, A; Ruys, A; Schindeler, A; Yu, NY | 1 |
| Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K | 1 |
| Godfrey, C; Little, DG; McDonald, M; Mikulec, K; Morse, A; Ramachandran, M; Schindeler, A | 1 |
6 other study(ies) available for zoledronic acid and Neurofibromatosis 1
| Article | Year |
|---|---|
Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation.
Topics: Animals; Benzamides; Diphenylamine; Disease Models, Animal; Mice; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Zoledronic Acid | 2021 |
Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bony Callus; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genes, Neurofibromatosis 1; Mice; Neurofibromatosis 1; Pseudarthrosis; Recombinant Proteins; Transforming Growth Factor beta; Zoledronic Acid | 2018 |
Maximizing bone formation in posterior spine fusion using rhBMP-2 and zoledronic acid in wild type and NF1 deficient mice.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Knockout; Neurofibromatosis 1; Neurofibromin 1; Osteogenesis; Pseudarthrosis; Recombinant Proteins; Spinal Fusion; X-Ray Microtomography; Zoledronic Acid | 2014 |
Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fracture Fixation, Internal; Fracture Healing; Fractures, Ununited; Imidazoles; Mice; Mice, Knockout; Neurofibromatosis 1; Postoperative Care; Pseudarthrosis; Recombinant Proteins; Tibial Fractures; Treatment Outcome; X-Ray Microtomography; Zoledronic Acid | 2011 |
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Neurofibromatosis 1; Osteoclasts; Osteoporosis; Zoledronic Acid | 2012 |
Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Topics: Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Survival; Cells, Cultured; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Energy Metabolism; Female; Femur; Haplotypes; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurofibromatosis 1; Neurofibromin 1; Osteoblasts; Skull; Tibia; Transforming Growth Factor beta; Zoledronic Acid | 2008 |